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Tumour necrosis factor a (TNF-a) in combination with melphalan
with or without the addition of g-interferon is presently used in the
treatment of patients with ￿in transit￿ metastases of malignant
melanoma and patients with locally advanced soft tissue sarcoma
(STS). In both groups of patients, the cytokine TNF-a and the
cytotoxic agent melphalan are used in isolated perfusion of the
limb (ILP). The efficacy in the treatment of locally advanced soft
tissue sarcomas, characterized by high response rates (>80%)
resulting in limb salvage in about 80% of the patients, has now
been well established by published reports of multicentre experi-
ences in up to 200 perfusions (Eggermont et al, 1993, 1996a,
1996b). Initially, the procedure was developed in the more tradi-
tional field of applying ILP, for example in the treatment of in
transit melanoma metastases, and high complete remission rates in
melanoma patients have been reported (Li￿nard et al, 1992, 1994).
The exact mechanism of TNF-a anti-tumour activity has not yet
been fully elucidated, but a number of theories exist (Sidhu and
Bollon, 1993). TNF-a has direct and indirect effects. It can induce
tumour-specific immunity (Spriggs and Yates, 1992) and is cyto-
toxic/cytostatic for some tumour cell lines in vitro (Dealtry et al,
1987). Its direct effect on tumour cells was proven shortly after the
discovery of the cytokine (Watanabe et al, 1988), but the indirect
effects probably play a more important role. The detrimental effects
on the tumour-associated vasculature is mediated by endothelial
cells (Shimomura, 1988), however, the effect on the microvascula-
ture seems to be dose dependent (Fajardo et al, 1992).
In contrast, high dosages of TNF-a exert a number of undesir-
able effects. The maximum tolerated dose (MTD) in humans is
350 mg m—2 (Brouckart et al, 1986; Asher et al, 1987) which is
10—50 times lower than the desired anti-tumour dose when given
intravenously. Because of severe toxicity, observed already at rela-
tively low doses of TNF-a after systemic administration, in phase
I/II clinical trials, virtually no tumour responses were observed
(Feinberg et al, 1988; Spriggs et al, 1988). This is not surprising
because TNF-a was never administered systemically at doses that
might have anti-tumour activity. This led Lejeune et al (1993) to
the development of the isolated perfusion with TNF-a together
with melphalan and g-interferon. The successful application of
TNF-a in this setting warrants that the applicability of TNF-a in
isolated organ perfusion setting is investigated. Isolated single-
lung perfusion with TNF-a proved to be safe (Pogrebniak et al,
1994; Weksler et al, 1994; Pass et al, 1996). Reports on the use of
TNF-a in isolated liver perfusion at the National Cancer Institute
in the USA (Fraker et al, 1994) as well as by our group (Borel
Rinkes et al, 1997) have appeared very recently.
Here, we report on the development of in vivo isolated kidney
perfusion and its anti-tumour effects in two tumour models.
MATERIALS AND METHODS
Animals
Male rats of the inbred WAG-Rij strain (Harlan CPB, Austerlitz,
The Netherlands), weighing 250—300 g were used. Rats were kept
under standard laboratory conditions. All rats were fed a standard
laboratory diet (Hope Farms, Woerden, the Netherlands). The
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the technique of isolated kidney perfusion. We studied the feasibility of a perfusion with TNF-a and assessed its anti-tumour effects in tumour
models differing in tumour vasculature. The maximal tolerated dose (MTD) proved to be only 1 mg TNF-a. Higher doses appeared to induce
renal failure and a secondary cytokine release with fatal respiratory and septic shock-like symptoms. In vitro, the combination of TNF-a and
melphalan did not result in a synergistic growth-inhibiting effect on CC 531 colon adenocarcinoma cells, whereas an additive effect was
observed on osteosarcoma ROS-1 cells. In vivo isolated kidney perfusion, with TNF-a alone or in combination with melphalan, did not result
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applicability of TNF-a in isolated kidney perfusion for human tumours seems, therefore, questionable.
Keywords: tumour necrosis factor a; isolated kidney perfusion; rats
433
British Journal of Cancer (1999) 79(3/4), 433–439
© 1999 Cancer Research Campaign
Article no. bjoc.1998.0067
Received 10 February 1998
Revised 14 May 1998
Accepted 21 May 1998
Correspondence to: AH van der Veen, Department of Surgery, University
Hospital Rotterdam Dijkzigt, Rotterdam, The Netherlands, PO Box 2040,
3000 CA Rotterdam, the Netherlandsexperimental protocols adhered to the rules laid down in the
￿Dutch Animal Experimentation Act￿ (1977) and the published
￿Guidelines on the Protection of Experimental Animals￿ by the
council of the EC (1986). The specific protocol was approved by
the ￿Committee on Animal Research￿ of the Erasmus University
Rotterdam, The Netherlands.
Tumour necrosis factor a
Recombinant human TNF-a (rhTNF-a) was kindly provided by
Boehringer Ingelheim, Ingelheim, Rhein, Germany. rhTNF-a had
a specific activity of 5.8 ´ 107 U mg—1 as determined in the murine
L—M cell assay (Kramer and Carver, 1986). Endotoxin levels were
less than 1.25 endotoxin U mg—1 protein. TNF-a was delivered in
0.5-ml vials in a concentration of 2.4 mg ml—1.
Melphalan
Melphalan (Alkeran, 50 mg per vial, Wellcome, Beckenham, UK)
was diluted in 10 ml of diluent solvent. Further dilutions were
made in 0.9% sodium chloride to give a volume of 0.5 ml in the
perfusion circuit.
Unilateral nephrectomy
It is probable that when two kidneys are perfused in vivo, kidney
function as measured by blood urea nitrogen (BUN), creatinine and
electrolytes remains stable after isolation and perfusion of one
kidney. To analyse to what extent renal function is compromised by
unilateral nephrectomy, five rats underwent a unilateral nephrec-
tomy and at regular intervals BUN, creatinine and electrolytes were
recorded. The right kidney was chosen for anatomic reasons. The
left kidney shows compensatory hypertrophy: the size of the kidney
is larger, there is a gain in cell volume and diameter of the
glomerulus as well as a larger volume of the tubule (Fine, 1986).
Operative procedures were carried out under clean conditions.
Anaesthesia was induced with ether (diethylether p.a. Merck,
Darmstadt, Germany). The abdomen was shaved and prepped with
ethanol 70%. Through a lumbotomy, the right kidney was exposed
and freed from its surrounding fat. Ureter, renal artery and vein
were dissected and tied with 4-0 silk sutures (B Braun, Melsungen,
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Figure 1 Course of kidney function parameters as a function of time (days)
after isolated kidney perfusion with 1 mg TNF-a in a roller-pump regulated
perfusion setting. After 15 min perfusion, urea and creatinine levels returned
to normal in sham (n) and 1 mg TNF-a groups (s), after 2 mg TNF-a (t) rats
were sacrificed after 2–3 days in bad clinical condition (values depicted are a
mean of six rats ± s.d.)
100mm
100mm
Figure 2 (A) Haematoxylin and eosin (HE) stained section (125 ´) of a
kidney 24 h after perfusion with perfusate only. See text for explanation.
(B) HE-stained section of a kidney 24 h after 15-min perfusion with 2 mg
TNF-a. Focal tubular necrosis is indicated (arrow)Germany). The right kidney was removed and the lumbotomy
closed with 2-0 silk in a running way. After 3 weeks, the animals
were sacrificed.
Perfusion fluid
In our experiments, a modified Krebs—Henseleit solution (sodium
chloride 118.00 mmol l—1, calcium chloride 2.52 mmol l—1, magnesium
sulphate 1.66 mmol l—1, sodium bicarbonate 24.88 mmol l—1, potas-
sium dihydrogen phosphate 1.18 mmol l—1 + D-glucose 5.55 mmol l—1,
sodium pyruvate 2.00 mmol l—1, mannitol 33.00 mmol l—1) was used
as perfusate.
Operative technique: isolated kidney perfusion (IKP)
Anaesthesia was induced with ether. A Zeiss operative microscope
(Carl Zeiss, Germany) was used. The abdomen was shaved and
prepped with ethanol 70%. Through a median laparotomy, the left
kidney and vessels were exposed in the retroperitoneum by sharp
and blunt dissection. Branches of the renal artery and vein (adrenal
and spermatic) were dissected when needed and temporarily
occluded with ligatures. A tobacco-pouch ligature was placed in
the vein with Nylon 9—0 (SSC, B Braun). A bolus of 50 IE heparin
(Heparin Leo, Weesp, the Netherlands) was injected intravenously.
Isolation of the renal artery and vein was carried out by means of
microvessel clamps. Via a venotomy and arteriotomy, the vessels
were cannulated with Silastic tubing (0.025 in. ID, 0.047 in. OD
and 0.012 in. ID, 0.025 in OD respectively, Dow Corning,
Michigan, USA). Another bolus of 50 IE heparin was added to the
perfusion circuit.
Perfusion model
Isolated kidney perfusion was performed to design a model resem-
bling isolated limb perfusion in which TNF-a is administered to
the oxygenated extracorporeal perfusion circuit. In this model, 1, 2
or 5 mg TNF-a was added to the perfusion circuit. Perfusion with
TNF-a was carried out for 15 min. Thus, TNF-a was allowed to
pass the kidney multiple times.
Flow through the kidney was regulated by a non-pulsatile roller
pump (Watson-Marlow 505U, Falmouth, UK). Perfusion pressure
was recorded on a Datex AS/3 monitor and kept between 100 and
120 mmHg, adjusting the flow generated by the roller pump
accordingly. Perfusion fluid was warmed to approximately 37°C
by countercurrent (Polyscience 210, Merck, Amsterdam, the
Netherlands). Temperature was recorded (Thermodig KJ-11,
Mera, Benelux).
Flow through the kidney was approximately 1 ml min—1. The
reservoir was gassed with carbogen (95% oxygen, 5% carbon
dioxide gas mixture), to keep the oxygen pressure of the perfusate
at 350—400 mmHg and the saturation at 99.5%.
When TNF-a and/or melphalan was added to the perfusion
circuit, a washout was carried out with 6 ml perfusion fluid (about
four times the intravascular kidney volume).
At the end of the perfusion period, the venotomy was closed by
tightening the tobacco-pouch ligature. Arteriotomy was closed
with Nylon 10—0 (SSC, B Braun). The laparotomy was closed with
silk 2-0 (B Braun) in one layer in a running way. Total operation
time varied between 90 and 120 min. Blood loss was kept to a
minimum.
During the recovery period, the animal was kept warm with a
200-W lamp and then returned to his cage.
Parameters and histology
Weight loss was recorded after operation. In the post-operative
period, the animals were observed at regular intervals for signs of
toxicity, and deaths were recorded. Clinical condition (skin, eyes,
stools and behaviour) was judged. Renal function was assessed
through blood urea nitrogen and creatinine levels as well as
electrolytes in plasma.
For histopathological analysis, two rats for each TNF-a concen-
tration were sacrificed 24 h after treatment. Kidneys were fixed
(emersion method) in 4% formaldehyde solution and embedded in
paraffin. Care was taken to keep the time of perfusion fixed, the
warm ischaemia period as short as possible, and time between
nephrectomy and fixation constant. Sections of the kidneys were
stained with haematoxylin and eosin.
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Figure 3 (A) Dose–response curve of CC531 colon adenocarcinoma to
melphalan in the absence or presence of various concentrations TNF-a,
as determined in the sulphorhodamine B assay (n, 0 mg ml–1 TNF-a; s,
0.5 mg ml–1 TNF-a; l l, 10 mg ml–1 TNF-a; for clarity concentrations between
0.5 and 10 mg ml–1 TNF have been omitted). (B) Dose–response curve of
ROS-1 osteosarcoma to melphalan in the absence or presence of various
concentration TNF-a, determined in the sulphorhodamine B assay (n,
0 mg ml–1 TNF-a; s, 0.5 mg ml–1 TNF-a; l l, 10 mg ml–1 TNF-a)
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dure was followed.
Tumour models
Colon carcinoma CC 531
The 1,2-dimethylhydrazine-induced, moderately differentiated
colon adenocarcinoma CC 531 (Marquet et al, 1984), trans-
plantable in syngeneic Wag-Rij rats, was used. The tumour is
weakly immunogenic, as determined by the immunization-chal-
lenge method of Prehn and Main (1957). The tumour was main-
tained in vitro in RPMI-1640 medium supplemented with 5% fetal
calf serum (virus and mycoplasma screened), 1% penicillin
(5000 U ml—1), 1% streptomycin (5000 U ml—1) and 1% L-gluta-
mine (200 mM). All supplementaries were obtained from Gibco
(UK). Before usage, the cells were trypsinized (5 min, 37°C),
centrifuged (5 min, 700 g), resuspended in RPMI-1640 and
counted. Viability was measured with trypan blue (0.3% in a 0.9%
sodium chloride solution). Viability always exceeded 95%.
For in vivo studies, the tumour was inoculated in the flank of
syngeneic Wag-Rij rats, where it was allowed to grow until the
time of the experiment.
Osteosarcoma ROS-1
The ROS-1 osteosarcoma (transplantable to Wag-Rij rats) was used
in the second series of experiments. This tumour originated sponta-
neously in the tibia of a rat. The ROS-1 cells grow as a monolayer
in Dulbecco￿s modified Eagle medium. To this medium, 5% fetal
calf serum and glutamic acid (Gibco, Paisley, UK) was added. Cells
were maintained in a humidified atmosphere of carbon dioxide/air
(5/95) at 37°C. From the tissue cultures, new solid tumours were
produced by serial inoculation in the flank, where it was allowed to
grow until the time of the experiment.
Experimental design
For in vitro testing of tumour cell lines for susceptibility to TNF-a
and melphalan, tumour cells were seeded at 1 ´ 104 cells per well
in flat-bottomed 96-well microtitre plates (Costar, USA) in a final
volume of 0.2 ml medium per well, and incubated at 37°C in 5%
carbon dioxide for 48 h in the presence of different concentrations
of rhTNF-a and melphalan. Concentrations of TNF-a used were
0.001, 0.01, 0.1, 1, 10 and 100 mmol ml—1. Concentrations of
melphalan used were 0.04, 0.1, 0.9, 5 and 8 mmol ml—1.
Growth of tumour cells was measured using the sulphorhod-
amine-B assay according to the method of Skehan et al (1990).
Eight replicate experiments were performed. Tumour growth was
calculated using the formula: tumour growth = (test well/control)
´ 100 per cent. The drug concentration reducing the absorbance to
50% of control (IC50) was determined from the growth curves.
For the in vivo isolated kidney perfusion (in vivo tumour
model) the subrenal capsule assay (SRCA) was used. Recipient
animals were anaesthetized with ether, a midline incision was
made and two small tumour fragments of 6—7 mg were placed
under the renal capsule of either kidney, one in the upper pole and
one in the lower pole of the kidney. To exclude perfusion defects
of the kidneys, the location of inoculation of CC531 and ROS-1
was varied between the upper or lower pole of the kidney. After 7
days, the animals were used for the experiments. At 14 days after
inoculation, the animals were sacrificed, the tumours were enucle-
ated and weighed. The tumours in the right kidney were used as an
internal control. Nine replicate experiments were performed.
Statistical significance was assessed using the Mann—Whitney
U-test.
RESULTS
Unilateral nephrectomy
Unilateral nephrectomy was very well sustained. There was a
minor increase in creatinine shortly after operation, but all animals
showed a quick recovery. Kidney functions fluctuated within a
normal range.
Sham perfusion
In five animals, isolated kidney perfusion with perfusate only was
performed (Figure 1). BUN and creatinine levels were elevated for
3 days, but returned to normal within 1 week. Blood levels were
followed for 3 weeks, but showed only fluctuation. After perfu-
sion, kidneys showed slight oedema, depending on perfusion pres-
sure. Perfusion pressure greater than 120 mmHg resulted in some
oedema, kidneys perfused with less than 120 mmHg showed no
oedema; thus, all perfusions with TNF-a were performed with a
pressure less than 120 mmHg. At sacrifice, no macroscopic abnor-
malities were seen. All rats survived the procedure.
TNF-a perfusion
After perfusion with 1 mg TNF-a, a rise in blood urea nitrogen
(BUN) and in creatinine levels was observed during the first 4
days after operation (Figure 1). In spite of this initial toxicity, all
rats survived the procedure and kidney functions returned to
normal after 6 days and remained within normal range. Animals
recovered their preoperative weight after a median of 25 days after
isolated kidney perfusion. Perfusion with 2 mg of TNF-a resulted
in a continuous rise of BUN and creatinine (Figure 1), and rats
were sacrificed in bad clinical condition. After 2 days, rats were
lethargic and had bloody diarrhoea. After isolated kidney perfu-
sions with 5 mg added to the perfusion circuit, rats died very
quickly because of shock and respiratory failure within 24 h (data
not shown).
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Figure 4 Growth inhibition of CC 531 adenocarcinoma and ROS-1
osteosarcoma in the subrenal capsule assay after isolated kidney perfusion
with 1 mg TNF-a combined with 500 mg melphalan (CC531–, sham; CC531+,
treated; ROS-1–, sham; ROS-1+, treated; data shown are mean values of
nine rats ± s.d. P = n.s.)Histology
Kidneys perfused with perfusate only did not show any major
changes in histology (Figure 2A).
In kidneys perfused with 1 mg TNF-a, no severe abnormalities
could be seen, but signs of focal tubular necrosis and bleeding
were seen in the 2 mg (Figure 2B) and 5 mg groups. Scattered
mononuclear inflammatory cells are present in the interstitium.
The glomeruli appeared to be relatively unaffected.
Animal weight
All animals showed a decrease in weight after the perfusion.
During the first week, weight gain was minimal, but 21 days after
isolated kidney perfusion the animals recovered their preoperative
weight.
In vitro sensitivity of the colon adenocarcinoma CC531
to TNF-a and melphalan
Cells of the CC531 tumour showed only a minor response to
increasing dosages of rhTNF-a as determined by the sulpho-
rhodamine-B assay. The IC50 of cells treated with more than 10 mg
ml—1 TNF-a was just reached, which means a significant reduction
in the number of tumour cells after 48 h of incubation (P < 0.05).
The dose—response curve of CC531 cells to melphalan alone
(0 mg ml—1 TNF-a) showed sensitivity in vitro at dosages higher
than 1 mg ml—1 (Figure 3A). The IC50 of melphalan is reached with
a concentration of > 10 mg ml—1. The cell line proved to be rela-
tively resistant to the cytotoxic effects of melphalan.
The IC50 of the adenocarcinoma cells to treatment with
melphalan was only slightly reduced in the presence of incre-
menting dosages of TNF-a (Figure 3A, for clarity only 0.5 and
10 mg TNF-a is shown). The maximal growth of CC531 is reduced
in the presence of TNF-a. Because the dose—response curves all
bend towards total growth inhibition, irrespective of the concentra-
tion of TNF-a, a synergy between the cytokine and the cytotoxic
drug in this tumour system in vitro could not be demonstrated.
In vitro sensitivity of the osteosarcoma ROS-1 to TNF-a
and melphalan
The dose—response curves of the ROS-1 osteosarcoma cell line to
TNF-a and melphalan are shown in Figure 3B. The osteosarcoma
cell line shows relative minor sensitivity to TNF-aalone (Manusama
et al, 1996a). The IC50 for melphalan is reached at 6 mg ml—1.
Maximum growth of the osteosarcoma in vitro at lower dosages
of melphalan is reduced in the presence of TNF-a at the various
concentrations used (for clarity only 0.5 and 10 mg ml—1 TNF-a
curves are shown). Total growth inhibition is reached with
increasing dosages of melphalan, almost independent of TNF-a.
These experiments, therefore, could not reveal synergism of TNF-
a and melphalan in the tumour cytotoxic effects, but an additive
effect at best.
Tumour response of CC531
In the SRCA, the relatively low concentration of 0.2 mg ml—1 TNF-
a had to be used. Kidney functions were severely disturbed at
higher dosages. Sham perfusion and isolated kidney perfusion
with 0.2 mg ml—1 TNF-a under oxygenated conditions showed no
significant inhibition of tumour growth (data not shown). There
was minor growth inhibition of the solid tumour in this location,
but none of the tumours showed regression.
A combination of the MTD of TNF-a (1 mg) and the dose used
in isolated limb perfusions of 40 mg melphalan was chosen at first
to investigate whether there were any synergistic or additive
effects in vivo. We could not prove significant growth inhibition
with this combination.
In subsequent experiments, we tested the combination of a high-
dose melphalan (500 mg) with the MTD of TNF-a (1 mg). These
experiments showed growth inhibition, but no significance was
reached (Figure 4, n = 9; treated vs control; mean 57 mg vs
81.11 mg, s.d. 12.59 vs 13.22, P = 0.1999).
Tumour response of osteosarcoma
In this tumour model, only minor sensitivity was shown to the maxi-
mally tolerated dosages of TNF-a and melphalan. Mean tumour
weight (n = 9; treated 76.0 ± 11.91 mg vs control 105.8 ± 12.76 mg;
P = 0.157) was only slightly reduced, again without significance
(Figure 4).
DISCUSSION
Isolated perfusion with tumour necrosis factor-a in combination
with ischaemia (Manusama et al, 1994) or with melphalan
(Manusama et al, 1996a, 1996b) has been reported to result in
complete tumour regression in preclinical tumour models. Isolated
limb perfusion in patients with in-transit melanoma with TNF-a in
combination with melphalan and g-interferon resulted in high
complete remission rates (Li￿nard et al, 1992, 1994). Also, high
limb salvage rates have been reported with the same treatment
protocol in patients with non-resectable soft-tissue sarcomas
(Eggermont et al, 1993, 1996a, 1996b).
Isolated organ perfusion with TNF-a is clearly a more compli-
cated matter than isolated limb perfusion. Different models have
been developed to evaluate the efficacy of TNF-a in organ perfu-
sion, such as in lung (Weksler et al, 1993, 1994; Pogrebniak et al,
1994), and in liver (Fraker et al, 1994; Borel Rinkes et al, 1997).
TNF-a in isolated lung perfusion has been shown to be safe, and in
a phase I study tumour responses have been observed in patients
with lung metastases (Pass et al, 1996).
The isolated perfused kidney model has been used to study the
effects of cytotoxic agents (Asbach and Bersch, 1980). Here, we
demonstrate that analogous to the isolated limb perfusion (ILP)
isolated perfusion of the kidney (IKP) is technically feasible.
In the current model, the MTD was reached at 1 mg of TNF-a,
showing only a transient renal toxicity. At 2 mg of TNF-a, fatal
renal toxicity was seen. This involved acute renal failure leading to
death by day 4. An acute fatal shock syndrome was noted at 5 mg.
It is known that TNF-a may have direct toxic effects to the
kidney (Tracey et al, 1986; Gaskill, 1988; Kahky et al, 1990).
Acute tubular necrosis was seen with portal infusion of sublethal
doses of TNF-a with relative sparing of the glomeruli. In
surviving animals, a decrease in kidney function was noted. The
serious toxicity seen in our experiments with higher dosages of
TNF-a may be partially explained by the production of TNF-a by
glomerular macrophages, mesangial cells and renal tubular cells
upon stimulation (Affres et al, 1991; Tipping et al, 1991; Baud and
Ardaillou, 1995). Analogous to the production of TNF-a and
interleukin 1 by Kupffer cells (Kahky et al, 1990), we hypothesize
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increased toxicity. In rats perfused with 5 mg, the secondary
cytokine response was so extreme that the rats die of acute respira-
tory distress. Similar observations have been reported by Fraker
et al (1994) in pigs, shown to be due to a secondary cytokine
response that could not be prevented by anti-TNF-a antibody
treatment. Toxicity to the lung is manifested by pulmonary
oedema and adult respiratory distress syndrome (Pogrebniak et al,
1994). Thus, in contrast to the very high concentration of TNF-a
that can be applied in the ILP setting, the kidney proves to be a
very susceptible organ which only tolerates 1/50th of the TNF-a
dose used in ILP.
In vitro, synergy between TNF-a and melphalan for the rat
colon adenocarcinoma cell line CC531 was not observed. Also,
synergy could not be proven for the osteosarcoma cell line ROS-1.
Here, an additive effect at best is reached.
For in vivo studies, two solid tumour systems were chosen with
a different vascularization pattern. The rationale for this choice is
based on our previous work with the highly vascularized soft
tissue sarcoma BN175, in which the synergistic anti-tumour
effects with the combination of TNF-a with melphalan were
shown to induce vascular changes accompanied by increased
vascular permeability and platelet aggregation (Manusama et al,
1996a; Nooijen et al, 1996).
The observations in our in vivo experiments made clear,
however, that no strong synergistic anti-tumour effects existed in
either tumour. Instead of the high concentration of 10 mgm l —1
TNF-a as used in isolated limb perfusion with ROS-1, the rela-
tively low dose of 0.2 mg ml—1 had to be used because of dose-
limiting toxicity. Thus, the minimal threshold concentration of
TNF-a was not reached and, therefore, the crucial vascular effects
in vivo described previously (Manusama et al, 1996a; Nooijen et
al, 1996) are not observed. Because isolated kidney perfusion in
the rat allowed only low dosages of TNF-a, the dual role of TNF-
a on the tumour vasculature may be an explanation for the
discrepancies between in vitro and in vivo results. It has been
demonstrated that low TNF-a concentrations are promoting
angiogenesis, whereas high concentrations of TNF-a are toxic to
the vessels (Fajardo et al, 1992). The concentration of TNF-a used
in isolated kidney perfusion is only 0.2 mg ml—1. At this concentra-
tion, a promotion of angiogenesis might even be more plausible
than the vascular destruction seen with higher dosages. Thus, the
typical effects of TNF-a are not seen, which is an explanation for
the absence of growth retardation in the tumour models used in our
experiments.
Although the model of isolated kidney perfusion was developed
to evaluate the effect of TNF-a in isolated organ perfusion, it is
also possible to treat kidney tumours with this regimen. Because
the main target of TNF-a is the vascular endothelium, well-vascu-
larized renal tumours could potentially be responsive. In a recently
published study of isolated perfusion of the kidney in a miniature
swine, it appeared possible to perfuse the kidney with 1 mg ml—1
(Walther et al, 1996).
We conclude from our studies with the isolated kidney perfusion
model that because only 1/50th of the TNF-a concentration was
tolerated the advantage of regional application is lost and perspec-
tives for efficacy in tumour-bearing species is much reduced. If the
dose needed for anti-tumour effect is 50 times higher than the
maximal tolerated dose in isolated kidney perfusion (Asher et al,
1987; Li￿nard et al, 1992, 1994; Eggermont et al, 1996a, 1996b),
the outlook for clinical applicability seems to be poor.
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